The rest of this story is for members
The rest is for members
The story continues: the full timeline, the transaction ranges, and the names the forms carry.
Premium comes through the Telegram channel. Already have a code? Sign in to activate it.
Premium
TNXP
Tonix: analysts see 239% potential and insider purchases
Canaccord Genuity sees almost 240% potential in pharmaceutical company Tonix, which is launching a new drug for fibromyalgia, alongside significant insider purchases.
Other Stories
Kendall: Jefferies sees almost 200% potential in the biotech company
PremiumAnalystsCADL2d ago2 min read
RAPP: positive results, the stock plunged, and the CFO bought
InsidersRAPP5d ago3 min read
Unusual insider purchase alert
PremiumInsidersMSM50m ago2 min read